(Q41563060)

English

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery

scientific article published on August 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

1 reference

Europe PubMed Central

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

adaptive radiation therapy

0 references

author name string

Balfour JA

1

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Goa KL

2

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

publication date

1 August 1997

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

273-298

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

https://scigraph.springernature.com/pub.10.2165/00003495-199754020-00008

0 references

Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Behavioural pharmacology of 5-HT3 receptor ligands

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron. Therapeutic use as an antiemetic

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple-dose, placebo-controlled, phase I study of oral dolasetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risks and benefits of drugs used in the management of postoperative nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous measurement of the major metabolites of dolasetron mesilate in human urine using solid-phase extraction and high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MDL 73,147EF, a 5-HT3 antagonist, facilitates latent inhibition in the rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of a reversed-phase HPLC method for directly quantifying the enantiomers of MDL 74,156, the primary metabolite of dolasetron mesylate, in human plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anaesthetic factors contributing to postoperative nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous measurement of dolasetron and its major metabolite, MDL 74,156, in human plasma and urine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of acute and chronic MDL 73,147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of dolasetron and its reduced metabolite in human plasma by GC-MS and LC

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The acute radiation syndrome. A memorial to William Michael Court-Brown

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The 5-HT3 receptor in mammalian brain: a new target for the development of psychotropic drugs?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-dose, placebo-controlled, phase I study of oral dolasetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postoperative nausea and vomiting. Its etiology, treatment, and prevention.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-HT3 receptors: pharmacologic and therapeutic aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/9257083

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199754020-00008

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41563060&oldid=2087558117"